Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Evaluating Renal Cell Carcinoma Risk Factors (MICRA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00927043
First received: June 22, 2009
Last updated: November 4, 2011
Last verified: November 2011

June 22, 2009
November 4, 2011
May 2009
September 2011   (final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00927043 on ClinicalTrials.gov Archive Site
  • Response rate. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Overall survival. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Response rate [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study Evaluating Renal Cell Carcinoma Risk Factors
Prospective, Multicenter, Epidemiological Study To Determine The Clinical, Molecular And Genetic Factors Associated To The Prognosis Of Patients With Advanced Renal Cell Carcinoma

This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.

invitation to volunteer

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:

Whole blood

Non-Probability Sample

Treatment naive patients with proven advanced RCC

Carcinoma, Renal Cell
Other: Epidemiological study according to clinical practice
Epidemiological study according to clinical practice.
1
Intervention: Other: Epidemiological study according to clinical practice
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
145
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
  • =18 years, any gender.
  • Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion Criteria:

  • Patients who have already initiated any kind of specific therapy for the treatment of RCC.2.
  • Patients with other neoplasias different from RCC (current or past).
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
NCT00927043
3066K1-4433, B1771010
No
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP